Cosmos Health Inc. COSM

Industrials SIC 5122 - Wholesale-Drugs, Proprietaries & Druggists' Sundries NAICS Wholesale Trade › Merchant Wholesalers, Nondurable Goods › Drugs and Druggists' Sundries Merchant Wholesalers derived Nasdaq

Cosmos Health Inc. was incorporated in 2009 in Nevada and is a diversified, vertically integrated global healthcare group, owner of proprietary pharmaceutical and nutraceutical brands, generics, manufacturer and distributor of healthcare products, engaged in research & development of innovative medicines and repurposing drugs as well as operator of a telehealth platform.

As a global company we are harnessing our expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern pharmaceutical and nutraceutical products.

We operate in the healthcare sector and particularly in the Pharmaceutical and Nutraceutical businesses. We cover vertically several process phases within the abovementioned sectors, such as research & development, manufacturing, marketing, sales and distribution of products and services. More specifically, we operate in generic medicines, nutraceuticals, biocides, medical devices, novel oncology drugs, drug repurposing and telehealth services.

Last close 0.26 2026-10-23
Market cap $26.3M 2026-06-30 share count
52-week range 0.16 - 1.05

Valuation FY2025 figures against the last close

P/S0.4x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.63

Where the revenue comes from as reported in the latest 10-K

Revenue by segment

  • Wholesale
  • Nutraceuticals and Pharmaceuticals
  • Pharma manufacturing
  • Other
Revenue by segment, 4 categories over 2 years. The same figures are in the table below. FY2025 Wholesale, FY2025: 59.3M (90.9%) 91% Wholesale Nutraceuticals and Pharmaceuticals, FY2025: 4.3M (6.5%) 7% Pharma manufacturing, FY2025: 1.7M (2.6%) Other, FY2025: 1.2K (0.0%) FY2024 Wholesale, FY2024: 51.6M (94.8%) 95% Nutraceuticals and Pharmaceuticals, FY2024: 2M (3.6%) 4% Pharma manufacturing, FY2024: 865.4K (1.6%) Other, FY2024: 0 (0.0%)
Segment FY2025FY2024
Wholesale $59.3M $51.6M
Nutraceuticals and Pharmaceuticals $4.3M $2.0M
Pharma manufacturing $1.7M $865.4K
Other $1.2K $0

As the company reported it, from the “SEGMENT REPORTING (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $65.3M$54.4M$53.4M$50.3M$56.2M$55.4M$39.7M$37.1M$30.0M$6.8M
Cost of revenue $57.4M$50.1M$49.0M$44.4M$47.9M$47.3M$36.0M$34.7M$28.1M$6.2M
Gross profit $7.9M$4.3M$4.3M$6.0M$8.3M$8.1M$3.7M$2.4M$2.0M$601.0K
R&D $519.4K$533.3K$164.9K———————
SG&A $15.6M$11.7M$19.6M$10.2M$9.2M$2.1M$3.3M$3.6M$4.9M$794.1K
Total operating expenses $24.6M$19.9M$26.2M$13.4M$12.9M$5.3M$3.9M$3.6M$6.8M$803.5K
Operating income -$16.7M-$15.5M-$21.8M-$7.5M-$4.5M$2.7M-$255.8K-$1.2M-$4.9M-$202.5K
Interest expense $1.9M$1.0M$866.5K$2.3M$2.8M$2.8M$1.4M$967.8K$748.5K$189.7K
Pre-tax income -$19.1M-$16.2M-$18.5M-$13.1M-$7.8M$1.2M-$3.1M-$9.0M-$6.2M-$600.2K
Income tax $0$0$0$775.1K$114.0K$377.5K$182.8K$17.3K$2.8K$769
Net income -$19.1M-$16.2M-$18.5M-$13.8M-$8.0M$820.8K-$3.3M-$9.1M-$6.2M-$601.0K
EPS, basic -0.63-1.17-2.15-33.16-23.740.06-0.25-0.68-0.490.00
EPS, diluted -0.63-1.17-2.15-33.16-23.740.06-0.25-0.68-0.4980,741.00
Shares, diluted (wtd. avg.) 30.3M19.1M12.0M1.9M656,93313.3M13.3M13.3M12.8M12.6M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $715.7K$315.1K$3.8M$20.7M$286.5K$628.4K$38.5K$864.3K$782.9K$716.6K
Short-term investments $46.2K$21.1K$20.1K$14.9K$11.5K$222.8K$238.9K$2.7M——
Receivables $19.6M$13.5M$19.8M$23.7M———$4.8M$1.3M$661.9K
Inventory $5.8M$4.4M$4.8M$3.5M$3.1M$3.3M$3.5M$3.2M——
Total current assets $38.4M$25.5M$36.6M$56.4M$39.8M$40.8M$21.2M$18.3M$9.5M$2.6M
Property, plant and equipment $10.6M$9.7M$10.3M$1.8M$1.9M$1.8M$1.7M$1.4M$114.6K$52.7K
Goodwill $49.7K$49.7K$49.7K$49.7K$49.7K$49.7K$49.7K$49.7K——
Other intangibles $7.5M$7.7M$7.8M$657.2K$436.1K$180.8K$214.0K$247.1K——
Total assets $65.5M$54.3M$66.0M$68.0M$49.4M$43.8M$23.9M$20.7M$10.7M$3.1M
Accounts payable $14.6M$11.2M———$12.0M$7.8M$5.9M$10.0M$2.9M
Short-term debt ————$578.9K—————
Total current liabilities $38.3M$25.8M$24.3M$21.7M$29.9M$34.3M$28.2M$22.3M$13.7M$4.9M
Long-term debt $3.8M$4.1M$4.6M$5.0M$477.6K$10.8M$0$145.5K——
Total liabilities $47.1M$29.8M$30.0M$28.4M$45.0M$48.0M$30.3M$24.0M$13.7M$4.9M
Retained earnings -$133.2M-$114.0M-$91.6M-$66.2M-$34.3M-$18.8M-$19.6M-$16.3M-$7.2M-$1.0M
Total equity $18.4M$24.5M$36.0M$39.3M$4.4M-$4.2M-$6.5M-$3.3M-$3.0M-$1.8M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$8.4M-$7.7M-$15.6M-$14.9M-$7.1M-$11.5M-$4.8M-$1.6M-$8.8M-$2.1M
Depreciation and amortisation $1.4M$1.2M$353.0K$70.1K$352.4K$240.9K$201.0K$34.6K$17.4K$9.4K
Stock-based compensation $2.3M$1.7M$577.9K$24.4K$5.9M——$242.0K$338.8K$16.6K
Capital expenditure $55.7K$418.1K$1.3M$74.2K$581.4K$117.7K—$503.4K$55.3K$12.8K
Investing cash flow -$2.0M-$798.3K-$13.8M-$21.5K-$826.8K-$117.7K$588.9K-$195.8K-$14.5K-$144.7K
Financing cash flow $14.1M$5.0M$12.7M$35.0M$7.3M$12.5M$3.6M$2.0M$9.3M$2.7M
Buybacks —$0$100.5K—$376.9K$200.0K————

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001477932-26-002278.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -25M 0 25M 50M 75M Revenue, FY2016: 6.8M Gross profit, FY2016: 601K Net income, FY2016: -601K Revenue, FY2017: 30M Gross profit, FY2017: 2M Net income, FY2017: -6.2M Revenue, FY2018: 37.1M Gross profit, FY2018: 2.4M Net income, FY2018: -9.1M Revenue, FY2019: 39.7M Gross profit, FY2019: 3.7M Net income, FY2019: -3.3M Revenue, FY2020: 55.4M Gross profit, FY2020: 8.1M Net income, FY2020: 820.8K Revenue, FY2021: 56.2M Gross profit, FY2021: 8.3M Net income, FY2021: -8M Revenue, FY2022: 50.3M Gross profit, FY2022: 6M Net income, FY2022: -13.8M Revenue, FY2023: 53.4M Gross profit, FY2023: 4.3M Net income, FY2023: -18.5M Revenue, FY2024: 54.4M Gross profit, FY2024: 4.3M Net income, FY2024: -16.2M Revenue, FY2025: 65.3M Gross profit, FY2025: 7.9M Net income, FY2025: -19.1M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $6.8M $30.0M $37.1M $39.7M $55.4M $56.2M $50.3M $53.4M $54.4M $65.3M
Gross profit $601.0K $2.0M $2.4M $3.7M $8.1M $8.3M $6.0M $4.3M $4.3M $7.9M
Net income -$601.0K -$6.2M -$9.1M -$3.3M $820.8K -$8.0M -$13.8M -$18.5M -$16.2M -$19.1M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 5122

TickerCompanyMarket capP/ERevenue growth
MCK MCKESSON CORP $116.68B 26.1x 12.4%
COR Cencora, Inc. $63.16B 41.6x 9.3%
CAH CARDINAL HEALTH INC $58.04B 34.5x 14.2%
HLF HERBALIFE LTD. $1.40B 6.1x 0.9%
NUS NU SKIN ENTERPRISES, INC. $233.2M 1.5x -14.3%
HWH HWH International Inc. $20.7M — -30.8%
MEDS DataMeds AI, Inc. $6.8M — 28.7%
HKPD Cellyan Biotechnology Co., Ltd — — —